TP53 and acute myeloid leukemia: Few prospectively tracked patients with DNMT3a, TP53, spliceosome genes and RUNX1 mutations at the time of the initial screening have developed AML within 7.4, 4.9, 6.7 and 1.5 years respectively (140).